Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.7.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Current assets    
Cash and cash equivalents $ 121,998 $ 158,779
Short-term deposits 18,000 22,694
Marketable securities - available for sale debt securities 80,023  
Accounts receivable, net of allowance for doubtful accounts of $- and $- 1,406 1,480
Other current assets and prepaid expenses (including current portion of clinical materials) 16,317 15,798
Total current assets 237,744 198,751
Restricted cash 4,156 4,017
Clinical materials 2,026 2,580
Property, plant and equipment, net 38,922 27,899
Intangibles, net 1,431 1,268
Total assets 284,279 234,515
Current liabilities    
Accounts payable (including amounts due to related parties of $- and $326) 4,577 11,350
Accrued expenses and other accrued liabilities (including amounts due to related parties of $- and $39) 13,372 17,528
Deferred revenue 12,304 11,392
Total current liabilities 30,253 40,270
Deferred revenue, non-current 20,754 24,962
Other liabilities, non-current 3,777 3,141
Total liabilities 54,784 68,373
Contingencies and commitments - Note 9
Stockholders' equity    
Common stock - Ordinary shares par value GBP 0.001, 701,103,126 authorized and 561,103,126 issued and outstanding (2016: 574,711,900 authorized and 424,775,092 issued and outstanding) 853 683
Additional paid in capital 448,985 341,200
Accumulated other comprehensive loss (16,854) (14,249)
Accumulated deficit (203,489) (161,492)
Total stockholders' equity 229,495 166,142
Total liabilities and stockholders' equity $ 284,279 $ 234,515